Prostaglandin EP2 Agonists for Intraocular Pressure Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly those involving ocular hypertensive conditions, lack effective ocular hypotensive agents that can efficiently manage increased intraocular pressure, which is a hallmark of glaucoma, and there is a need for more targeted therapeutic options beyond traditional β-adrenoreceptor antagonists.
Innovation Solution
Development and use of specific prostaglandin EP2 selective agonists and their derivatives, such as certain compounds with formulas provided, which are administered as medicaments to treat and prevent glaucoma and ocular hypertension by reducing intraocular pressure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional β-adrenoreceptor antagonists are used to treat glaucoma, then intraocular pressure can be reduced, but the treatment lacks effectiveness in certain ocular hypertensive conditions and offers limited therapeutic options
Solution Approach 1:
The patent applies parameter changes by developing new chemical compounds with modified molecular structures (prostaglandin analogs with specific substitutions at positions 1, 3, and 9) to achieve improved pharmacological activity. These structural parameter changes result in compounds that more effectively reduce intraocular pressure across various glaucoma types while maintaining selectivity for ocular tissues.
Solution Approach 2:
The patent employs composite materials by creating hybrid molecular structures that combine features of prostaglandins with specific cyclic and acyclic substituents. These composite molecular architectures provide both the core prostaglandin activity for pressure reduction and additional functional groups that enhance tissue selectivity and duration of action.
2Stress or pressure
If current ocular hypotensive agents are used, then some reduction in intraocular pressure is achieved, but effective management of increased intraocular pressure in various glaucoma types remains insufficient
Solution Approach 1:
The patent implements universality by designing compounds that can effectively treat multiple types of glaucoma (open-angle, angle-closure, post-surgical, post-laser) with a single medication. The molecular structure incorporates functional groups that enable broad-spectrum activity across different ocular hypertensive conditions while maintaining consistent pressure reduction efficacy.
Solution Approach 2:
The patent applies segmentation by dividing the prostaglandin molecule into distinct functional regions: a core cyclic structure for receptor binding, side chains for metabolic stability, and specific substituents for enhanced ocular selectivity. This segmented design allows each portion to contribute independently to the overall therapeutic effect.
Data Source
AI summary
The compounds disclosed herein are useful for treating glaucoma, ocular hypertension, and baldness.